Is Tonix Pharmaceuticals Holding going out of business?

Tonix Pharmaceuticals Holding Corp. (TNXP) Fundamentals

A quick summary of the latest filed figures while the full analysis loads.

Tonix Pharmaceuticals Holding Corp. (TNXP) scores 27 out of 100 on fundamentals, Distressed / Caution, based on SEC filing data.

Leading signal: Shares dilution YoY: 128.91% (YoY)

Five questions, kept separate

Survival - Fragile

17-24 mo of estimated runway from 2026-06-30, based on $176M of cash and short-term investments against $103M of annual burn. A disclosed filing event caps this reading; Event Risk carries the detail.

Business quality - Pre-commercial

Operating margins cannot grade a pipeline; Survival and clinical evidence remain the relevant lenses here.

Trajectory - Clinical progress unavailable

Fundamentals can show funding and burn, but not whether the clinical pipeline is advancing.

Valuation - Reasonable

123.2% net-cash backing support a reasonable pre-commercial Valuation assessment.

Event risk - Critical event risk

Going-Concern Warning is the decisive filing event; one adverse event family is active. Favorable events are shown separately and do not offset adverse risk.

What the rules read

• Shares dilution YoY: 128.91% (YoY)
• Debt / Equity: -0.79x (Net Cash)
• ROIC: -220.00%
• Filing event risk: Going-Concern Warning (-8 pts)
• Revenue growth YoY: 577.88% (YoY) - Growth from a low base; sustainability uncertain.
• Return on Assets: -48.81%
• Revenue per Asset Efficiency: 99.88% QoQ (Strong monetization)
• FCF margin: -787.46% (Inv. Mode)
• Cash Runway (years): 1.71y
• Asset Growth Velocity: 35.62% YoY (Scaling infra)
• Cash Burn Deceleration: -0.20% QoQ improvement (Worsening)
• Working Capital Efficiency: 75.76x (Well-funded)

Read from filings through 2026-10-02.

Price as of 2026-09-26.